Peer-influenced content. Sources you trust. No registration required. This is HCN.

CMEZone.comRebalancing Risk–Benefit With Buprenorphine: An Atypical Opioid Analgesic

1.0 AMA PRA Category 1 Credit™
1.0 ACPE contact hour (0.1 CEU)

Release Date: May 1, 2022
Expiration Date: May 1, 2023

Learning Objectives
After completing this activity, participants should be better able to:

  • Describe the pharmacologic and safety differences between conventional and atypical opioids.
  • Recognize appropriate patients who might benefit from buprenorphine as a first-line opioid analgesic.
  • Understand how to transition opioid therapy from full µ-opioid analgesics to buprenorphine when appropriate.
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form